A four-in-one pure nanomedicine for synergistic multi-target therapy against breast cancer. Issue 42 (11th October 2021)

• Record Type: Journal Article
• Authors: Zhang, Rui; Cheng, Ge; Liu, Shengnan; Lv, Hongying; Li, Juan
• Is Part Of: Journal of materials chemistry. Volume 9:Issue 42(2021)
• Page Start: 8809
• Page End: 8822
• Publication Date: 2021-10-11
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d1tb01820e
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Novel four-in-one RRX/BMS/CA4/PTX NPs were used to target tumour cells, MDSCs, CSCs, PD-L1 and tumour microvessels for multi-target therapy of tumour. Abstract : Designing a multi-target nanomedicine without a carrier is pivotal for successful cancer nanotherapy. This study details a novel four-in-one RRX/BMS/CA4/PTX nanomedicine by simple nanoprecipitation. In this multi-target pure nanomedicine, paclitaxel (PTX) causes the immunogenic cell death of 4T1 tumour cells and the differentiation of marrow-derived suppressor cells (MDSCs) into dendritic cells (DCs) at low dose; repertaxin (RRX) selectively depletes cancer stem cells (CSCs) that are not killed by paclitaxel to inhibit lung metastasis from the breast; BMS-1 blocks the PD-1/PD-L1 pathway for proliferating effector T cells; and combretastatin A4 (CA4) targets tumour microvessels to cut off the blood supply in the tumour microenvironment. The synergy of multi-target therapies results in excellent antitumour effects. The tumour inhibition rate of 4T1 tumours is 92.5%, and the lung metastasis suppression rate exceeds 90%; no relapse is observed at 46 days after the treatment endpoint, and the survival of 50% of mice is prolonged by 95 days. Due to the low dose of PTX administration, the systemic toxicity of the RRX/BMS/CA4/PTX nanomedicine is not found. Our results suggest a strategy for designing multi-target pure nanomedicines with simple construction and efficacious therapeutic responses that present potential for clinical transformation.